Drug modulation of activity of microRNA generation in functional disorders of the gallbladder and sphincter of Oddi in children
Background. Functional disorders of the gallbladder and sphincter of Oddi are highly relevant in pediatric gastroenterology. The purpose of the study was to improve the treatment for functional disorders of the gallbladder and sphincter of Oddi in children based on studying the activity of microRNA generation. Materials and methods. Seventy children with functional disorders of the gallbladder and sphincter of Oddi were examined. Fifty patients received standard therapy in combination with ursodeoxycholic acid as a suspension formulation of Ukrliv®, and 20 patients received standard therapy without ursodeoxycholic acid. Prior to treatment and after the end of therapy, a molecular genetic study was carried out in all children to determine the level of microRNA-378f, microRNA-4311, microRNA-4714-3p expression in the blood serum using real time polymerase chain reaction. Results. It was found that in children with functional disorders of the gallbladder and sphincter of Oddi after the treatment with ursodeoxycholic acid, there was a probable decrease in the levels of aspartate aminotransferase from 34.96 ± 1.31 n/l to 26.18 ± 0.97 n/l, alkaline phosphatase from 507.92 ± 19.94 n/l to 359.53 ± 16.59 n/l in the blood serum and an increase in the contractile function of the gallbladder from 23.44 ± 1.56 % to 45.56 ± 1.68 % (p < 0.05). It was found that after standard therapy in combination with ursodeoxycholic acid (Ukrliv® suspension) in children with functional disorders of the gallbladder and sphincter of Oddi, the level of microRNA-378f expression was close to 5.23 ± 0.70 c.u., which was statistically significantly higher than before therapy (p < 0.05). On the background of standard therapy with and without the addition of ursodeoxycholic acid, the expression profile of micro-RNA-4714-3p in the blood serum of the examined children from groups 1 and 2 decreased significantly sharply to the level of 1.93 ± 0.58 c.u. and 1.14 ± 0.53 c.u., respectively (p < 0.05). Conclusions. The findings showed that under the influence of ursodeoxycholic acid, clinical and paraclinical manifestations of functional disorders of the gallbladder and sphincter of Oddi in children are regressed. The unique property of ursodeoxycholic acid in the form of Ukrliv® suspension has been revealed — to affect the activity of microRNA-378f and microRNA-4714-3p generation, which are gene regulators of cellular mechanisms, that influence the gene expression at the post-transcriptional level.
Full Text:PDF (Українська)
Volosoveс OP, Zubarenko OV, Kryvopustov SP, et al. Pediatrija (gastroenterologija ta patologija rann'ogo viku): navchal'nyj posibnyk [Pediatrics (gastroenterology and pathology of the early age): a study guide]. Odesa: Druk Pivden'; 2017. 165-180 pp. (in Ukrainian).
Tyazhka OV, Smіshchuk VV, Bryuzgіna TS. Importance of bile biochemical studies as an indicator of fatty acids, phospholipids and cholesterol metabolic disorders in children with cholelithiasis. Perinatologiya i pediatriya. 2015;(61):63-67. doi: 10.15574/PP.2015.61.63. (in Ukrainian).
Ministry of Нealth of Ukraine. Order on January 29, 2013 № 59. On Adoption of Standardized Clinical Protocols of Medical Care for Children with Diseases of the Digestive System. Available from: http://old.moz.gov.ua/ua/portal/dn_20130129_0059.html. Accessed: January 29, 2013. (in Ukrainian).
Finch ML, Marquardt JU, Yeoh GC, Callus BA. Regulation of microRNAs and their role in liver development, regeneration and disease. Int J Biochem Cell Biol. 2014 Sep;54:288-303. doi: 10.1016/j.biocel.2014.04.002.
Statistics about the current Human GENCODE: Release 27 (GRCh38.p10). Available from: https://www.gencodegenes.org/human/release_27.html. Accessed: Jan 2017.
Tabibian JH, Lindor K. Ursodeoxycholic acid treatment in primary sclerosing cholangitis. In: Forman LM, editor. Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Developments. Geneva, Switzerland: Springer International Publishing; 2017. 145-152 pp. doi: 10.1007/978-3-319-40908-5_11.
Copyright (c) 2019 CHILD`S HEALTH
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2020